Rhumbline Advisers Kala Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.3 - $1.31 $20,415 - $89,146	-68,051 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$0.61 - $1.84 $890 - $2,686	1,460 Added 2.19%	68,051 $94,000
Q4 2021 Feb 10, 2022	SELL	$1.16 - $2.74 $34 - $82	-30 Reduced 0.05%	66,591 $81,000
Q3 2021 Nov 12, 2021	BUY	$2.62 - $5.43 $4,708 - $9,757	1,797 Added 2.77%	66,621 $175,000
Q2 2021 Aug 05, 2021	BUY	$5.06 - $8.15 $37,535 - $60,456	7,418 Added 12.92%	64,824 $344,000
Q1 2021 May 06, 2021	BUY	$6.24 - $9.58 $13,877 - $21,305	2,224 Added 4.03%	57,406 $387,000
Q4 2020 Feb 10, 2021	BUY	$6.28 - $8.79 $17,646 - $24,699	2,810 Added 5.37%	55,182 $374,000
Q3 2020 Nov 12, 2020	SELL	$7.5 - $11.11 $60,187 - $89,157	-8,025 Reduced 13.29%	52,372 $393,000
Q2 2020 Aug 13, 2020	BUY	$8.33 - $13.79 $222,727 - $368,717	26,738 Added 79.44%	60,397 $635,000
Q1 2020 May 06, 2020	BUY	$3.83 - $8.79 $13,175 - $30,237	3,440 Added 11.38%	33,659 $296,000
Q4 2019 Feb 05, 2020	BUY	$3.36 - $4.81 $5,644 - $8,080	1,680 Added 5.89%	30,219 $112,000
Q3 2019 Oct 23, 2019	BUY	$3.57 - $6.58 $7,843 - $14,456	2,197 Added 8.34%	28,539 $109,000
Q2 2019 Aug 14, 2019	BUY	$4.93 - $8.8 $34,076 - $60,825	6,912 Added 35.57%	26,342 $168,000
Q1 2019 May 01, 2019	BUY	$5.19 - $8.97 $21,663 - $37,440	4,174 Added 27.36%	19,430 $161,000
Q4 2018 Jan 31, 2019	BUY	$4.29 - $9.94 $65,448 - $151,644	15,256 New	15,256 $75,000
Q3 2018 Nov 07, 2018	SELL	$9.54 - $13.87 $102,755 - $149,393	-10,771 Closed	0 $0
Q2 2018 Aug 06, 2018	BUY	$13.3 - $17.49 $143,254 - $188,384	10,771 New	10,771 $148,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $8.67M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.